GENE gtglabs.com: Earnings growth forecast for next year
An assessment of the EPS trend for the coming year confirms the resilience of patents and insurance coverage. Profit growth is driven by the expansion of AI diagnostics in clinics and the high margins of consumables. The uniqueness of early cancer detection methodologies allows Genetic Technologies (GENE) to flexibly manage its pricing power. Meanwhile, the 0.00 mark serves as a key metric reflecting the current analyst consensus forecast.
Metric breakdowns and analytics for Genetic Technologies Limited (GENE)
- price and consensus price forecast:
- company stock capitalization data:
- book capitalization indicators:
- debt level and financial liquidity data:
Total Debt to Capital Genetic Technologies|GENE - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Genetic Technologies Ltd|GENE - Company Cumulative Indebtedness|Debts to Book Capitalization Genetic Technologies|GENE - Long-Term Debt Volume|Company Short-Term Debts Genetic Technologies|Quick Liquidity Indicator gtglabs.com
- earnings and valuation multiples information:
GENE - Final Profit|Future Profit Genetic Technologies|GENE - Market Price to Net Income Ratio|Forward P/E Multiple Genetic Technologies Ltd|GENE - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Genetic Technologies|GENE - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Genetic Technologies|GENE - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months gtglabs.com|GENE - Earnings per share growth this year|Net earnings per share growth forecast for next year Genetic Technologies
Fundamental valuation:Genetic Technologies, GENE
This indicator measures the consensus earnings per share (EPS) growth forecast, allowing investors to filter out market noise and determine the direction of institutional expectations. By analyzing the EPS growth benchmark for Genetic Technologies (GENE) for the coming year, one can assess how the scalability of AI algorithms in mass screening offsets high R&D costs, transforming technological potential into actual financial growth.
Competitor analysis
Net earnings per share growth forecast for next year Agilent Tech|Quest Corp (DGX) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year ILMN|exactsciences.com (EXAS) - Net earnings per one share growth forecast for next year|Earnings growth forecast for next year RVTY (Revvity)|Bio-Rad Laboratories, Inc. (BIO) - Expected net earnings per share growth next year|NNNN - Net earnings per share growth forecast for next year|SHC (Nordion) - Projected earnings per share growth rate for next year|QDEL: Earnings growth forecast for next year|Expected net earnings per share growth next year opko.com (OPK)|Expected earnings per share growth for next year CDNA|MRVI (Maravai LifeSciences Holdings) - Projected earnings per share increase next year|Earnings growth forecast for next year FLGT|Consensus forecast of earnings per share growth for next year Standard BioTools Corp|Earnings growth forecast for next year CTKB (Cytek Biosciences, Inc.)|OSUR - Expected earnings per share growth for next year|XGN: Expected earnings per share growth for next year|Expected earnings per share trend next year MDXH (MDxHealth S.A.)|LUCD (Lucid Diagnostics Inc) - Expected earnings per share growth for next year|PRE: Projected earnings per share increase next year|IMDX (Insight Molecular Diagnostics, Inc.) - Earnings growth forecast for next year|Expected net earnings per share growth next year Trinity Biotech Corp TRIB|Earnings growth forecast for next year PRPH|Expected earnings per share growth for next year Ainos Inc AIMD|Earnings growth forecast for next year CODX (Co-Diagnostics Corp)|Expected earnings per share trend next year HSCS|BMRA - Net earnings per share growth forecast for next year|CDIO (Cardio Diagnostics) - Projected earnings per share growth rate for next year|Onconetix (ONCO) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Virax Biolabs Group Limited (VRAX)|Net earnings per share growth forecast for next year Bluejay|Net earnings per share growth forecast for next year AWH|Net earnings per share growth forecast for next year Accelerate Diagnostics (AXDX)|CNTG - Expected net earnings per share growth next year|Earnings growth forecast for next year ENZ (Enzo Biochem)|Net earnings per one share growth forecast for next year Fresh2 Group Ltd|23andMe Inc. - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year Psychemedics Inc PMD
